{"id":813429,"date":"2025-02-14T09:03:45","date_gmt":"2025-02-14T14:03:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/"},"modified":"2025-02-14T09:03:45","modified_gmt":"2025-02-14T14:03:45","slug":"in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/","title":{"rendered":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Feb.  14, 2025  (GLOBE NEWSWIRE) &#8212; February 14, 2025\u00a0\u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9UCvMCO-T00CTOZtRVtCR1le8vr6RuU3QSg_fZd_OiclJlL1kXiFViRKER1bM3FVPFhmrdiiV7LmYloxozohmeSFSqFpAv6LUTpYjl72H3_A7I4AvWOC1shFwZbPnKZZWnqFQRnzmnjVS6Oc6YYxjl5OjaOKysfJ5gOWz3WhcvBFXkRht5glwRyIJONDmY0m0tSK0PxEjVnP2aP6uueMfcwXjmLTJX3B2XXPdliNIOgt4wkMQ3jrVGt32-xYqZyNkvUz3e3D0xeZbAkBvx9iF8OrntZrZbJ5PoKpkzBztOWbVNFSkkE3vSPnKvOcq9AxgD3nX0JFFoeGbGPcpG0-Yr2toMYqfXCyZjgc6abfayHvfPRaK0TJob5YWd925mH2\" rel=\"nofollow\" target=\"_blank\">IN8bio, Inc<\/a>. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation &amp; Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100\u2019s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML) patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology.<\/p>\n<p>The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival (PFS) rate across all leukemia patients stands at 90.9%, and 1-year overall survival (OS) is 100%, outperforming real-world historical controls. These data demonstrate that results for INB-100 do not appear to be due to imbalances in patient selection criteria, the performance of the individual clinical centers or driven by specific transplant or lymphodepletion protocols. These data underscore INB-100\u2019s potential to reshape post-transplant care by leveraging gamma-delta T cells to enable sustained cancer cell surveillance and long-term remissions.<\/p>\n<p>\u201cAML patients undergoing allogeneic HSCT face high relapse rates with limited post-transplant therapeutic options,\u201d\u00a0said William Ho, Chief Executive Officer and co-founder of IN8bio.\u00a0\u201cThe durability of response and safety profile observed to date with INB-100 support its potential to set a new standard in post-transplant leukemia management.\u201d<\/p>\n<p>\u201cDespite decades of progress in transplantation, relapse remains the primary driver of mortality in AML patients post-HSCT. The INB-100 data showing durable remission without maintenance therapy is highly encouraging,\u201d said Dr. Michael Bishop, Director of the Hematopoietic Cellular Therapy Program, Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago and IN8bio Scientific Advisory Board member.<\/p>\n<p>\n        <strong>Key Phase 1 INB-100 Findings:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Zero Relapses in AML Patients:<\/strong>\u00a0No relapses observed in any AML patient treated with INB-100, with a median follow-up of over 20 months.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Superior 1-Year Survival Rates:<\/strong>\u00a0PFS at 90.9%, OS at 100%.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Favorable Safety Profile:<\/strong>\u00a0No cytokine release syndrome (CRS), neurotoxicity (ICANS), or Dose Limiting Toxicities (DLT\u2019s). No treatment-related deaths.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Gamma Delta T Cell Persistence and Expansion:<\/strong>\u00a0Evidence of in vivo expansion and long-term persistence, reinforcing the therapy\u2019s potential to maintain immune surveillance against residual leukemic cells.<\/li>\n<\/ul>\n<p>With approximately 20,000 new AML cases and ~11,500 deaths annually in the U.S., AML remains an area of high unmet medical need. Post-HSCT relapse occurs in up to 50% of patients, highlighting the urgency for novel, more durable therapeutic approaches. INB-100 harnesses the innate tumor-targeting properties of gamma-delta T cells to improve long-term outcomes, potentially filling a critical treatment gap.<\/p>\n<p>IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company\u2019s FDA discussions confirmed that relapse-free survival (RFS) is an acceptable primary endpoint for a future potentially pivotal randomized controlled trial in AML patients.<\/p>\n<p>IN8bio recently hosted a Key Opinion Leader webinar discussing the latest developments in gamma-delta T cell therapy and the promising INB-100 clinical data. The webinar featured insights including Dr. Michael Bishop. A replay of the February 11, 2025 webinar is accessible <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NW_FrVLD-wMEgmm0BsgGPa1HWpLxFHH3HYP0HsVXjfMlymA2xvSfwazuVtvtXo4_zT_4oF18Ie_Kq0eLsDvI_ZlzeR0A4HHB62NnrKaNAd4WEX9A2esXAL0G4tAhn5wmkcoA_zFuDgR0MR-S1MUHnJgjdoBWDid4uKgwld0pmQmOnzuFkeitqtdH65JgCOB1Hq4zeZfgU-OEiUAgQjnVOSHVA5gqugzYXz_Z3_60zHMgg4HQTeEwk25Fp_pLuXXLRcyNSf5JrT8S_wqmNhHzd66p-KuAfqqCTXqnENaMpEyq3AHKo8vd9gPX0bTn722sM-xnwmSyji7lu-cu21cZk-j90U65fbHryBENvReVjGr2toCQbxDnmmS2V6pxOqxxiTVdppU8uS6wUHzsF2K-Y9hjGI_8USjF078OZDcNH3o=\" rel=\"nofollow\" target=\"_blank\">here<\/a> on the company\u2019s website.<\/p>\n<p>\n        <strong>About IN8bio<\/strong><br \/>\n        <br \/>IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company\u2019s lead program, INB-100, is focused on AML evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F_8xMqicAl27JekE5FxycBJvIzVSOEYIK15NmZXpRhjl3JF_P0s_coI23izgZQ2tgJu1rbjQyvjffItagvWzR5fySdScTxA-OT-JDsBS_zlzfkELJJMrjg6cDQLiLjq7X6N-aFq6-SXopHb6K1c_DSC_84mX2dPkNjCJbGSEgxh9JhAlmWgEFDvojzShW8M5Hsy2U--GoBVJzAMWCj0iYKK5OmvwPjHYxk_rxZ68dUaCqZ-U96qQmqzhOuqLv1qKo-w8zmhsz4LkmaRNKqcITinPPjZAQY58FwqIu2IZlhoN5HR9K4yyFPpK7h5VZe_EzJNTTsFnYCAGTbN3ZITTOOcFdwGEGoZAZFW_O8QRhfWx3C5AXZBsxADI_UrwD9rriEFQ4ylSQKhNnr612k2X7T9hyRodVYovAMaRvpTBPn-MgULZumH6RkRXT6249xp8q5pgJcJmpGZLLOsYgrUBkQKbZD9BxFvmoKOpokKRIN55_QvyehO_J1AhfR8XL9s80-vqR8ixfCaeRd04IifZAg==\" rel=\"nofollow\" target=\"_blank\">www.IN8bio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: IN8bio\u2019s ability to deliver on the potential of INB-100; the potential of allogeneic INB-100 gamma-delta T cells to provide durable long-term, relapse-free remissions in high-risk or relapsed AML patients undergoing HSCT; the ability of INB-100 to help preserve the quality of life of AML patients and to become an attractive cellular therapy with the potential to extend survival in this difficult-to-treat patient population; IN8bio\u2019s ability to achieve anticipated milestones, including expected presentations and data readouts from its trials, enrollment of additional patients in its clinical trials, and advancement of clinical development plans; IN8bio\u2019s ability to de-risk INB-100\u2019s path toward a potential registrational trial and achieve future approval and broader patient access; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio\u2019s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio\u2019s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of our development programs, or even terminate its operations; IN8bio\u2019s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio\u2019s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio\u2019s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled \u201cRisk Factors\u201d in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.<\/p>\n<p>\n        <strong>Investors &amp; Company Contacts:<\/strong><br \/>\n        <br \/>Glenn Schulman, PharmD, MPH<br \/>203.494.7411<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J1UMphSULteQqUh5P3bsbxqzHANZVjLrbdS6kx7Tfzfk0ViR_2AaZucQvRbSb910S8DlnYAwmADwW35K5NCBeP006s5F6As5tMH6Pj7zfUiHLytVbBd_FH_2ldj7izr8u-3WQSfr5kE-wx3R5zW9oz_-yjW3cnAvKJxiiG4kZufm11Sc3q6DilJ7yUZQm5Fkfw7hIXYnNwQPtO50ZPrqKE1O4Z2TARGkV6nDOuSi_64LNFKuonH2djro7iwbYNMKWDh1p60g1DjrrdyNjNBDk_ik-OIjIhzqbT_XW7P-K9f8vwZ1wo5Z2h1hX0wHFDFfh22FVAd1b0er8fiGghL_KzB57HgbjnVu0dUMCuYNqUEQJJ6YEvnSiHyWCM64FulfgAheRBsDsIh3k96KxsxfAzyQUUaqA-fcetAOAqkxs1YKUIXSXdpcbVjbBJBw-FobSjuX7Hsmmax3EwIST_Z9PQbx8MLx1ZIiGQxl6GRkBQVLpDb2LAI6-MhPPOqBpalW0UVuTrTfnuj7V1JrdvgfBWmbOiyPFdc3mOLSSx7P6UoTXxIw-KBbjyRDm9NfRA1e\" rel=\"nofollow\" target=\"_blank\">gdschulman@in8bio.com<\/a><\/p>\n<p>IN8bio, Inc.<br \/>Patrick McCall<br \/>646.933.5603<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BLfOalSFY2ODRgt2_rQQ-Ga8GorOImn59z2109x4-qVJG8CmCXwH50Weh4y69DQoqaRFEEeAJjylFKz0J0ohkwYtbbdK3M2kfrMN2s65MEI_ir-8XgQaLv_B214LyZ1FAVhk6wHiKWgvZjE2fNyM8zAK36r3fnapeEvk0ZuDcmKV4VZanY2iq1smLRn1ZHPJTFP0F7ce1ZzNEFlmiv7KEu5oJSNGEgZSMg2EfgZR5XeP5Vbo_1yHdyUH2PxzVc9ELi11erApyiVIII2mJ9vAu8l6-F24V7pvxdcHo9qwdKCGwD8aleum_XsKDkrM5hYErnTfRDix9YEhn7hhgCQn_ZmMHxl72agbDeSxBbimwzbfevtj0FgDhbemo5kVqIE07Gl3TIQCn2K8pb9Q50i1UNNCNjk2iSEGGcovGOiIYP5cFp3epvdz8CG_GbsTrCsw1l_RIa8pXYfRQfPCIhnQ15TzPZipEvpqcN3twKN3uIyIwU-VnhPBzylCIw2WsSW2GbK3tGh9L1vkAFQAX-13BAFoI78jlTE2W6lXFVmyZfepJG3oWzN9BBrX9uryRNU5\" rel=\"nofollow\" target=\"_blank\">pfmccall@IN8bio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Kimberly Ha<br \/>KKH Advisors<br \/>917.291.5744<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0zOtfzHJ53Bv4C9JiZlxaCBEWttPAZxFZi55wAbGMwQobMqOWzaSyz6tO1aPUMceGpRsPVk0JoUP4xdrb1Y6ybZz8JyW6Hc4sKfPxaGLDs6ugmlg-DCn8-yxpLmIvv8GaCgUsYtMKodz_RfnHvCjZgSJuMznGNr0MS_JAwLTGu5_adQxxR3BG4MgVP1BQWAaJ7jCtvpk3zy2ex5tAgzGh0WQfzvocL6EfppRcjRPpjmDMcPSevbbkJfCSPG78tyD1MMwYHdpQwrBrmNn-bYFVCp2ypLFBC8wPARpHh1l5-XtlSUVUMsZCfcYPPX1HJ6UxTkYkIB4NuQWzzVg2L_LqdcudmsU-gficVPQheOePBjbXRYkfe7Zf8Tyawb-uYcNu1v5CKdIsA43x5YxDWJXGr6SMiRtsBLVCRGfhpqUbHMH62JTQ7SsjkfqJteaY3L1pQXUqmSuc7XJ7SAoZXi4TA6UgOtoifKptltNE5vCBogLsbCjGSptSj41SeRCLwIBNzFjm1RmQkPmhNWHICmf34H6Jr7cw7XAqKJ77zbTjVOoBQo0JCM0wN2iRjN_vw01-EtORlKL-UMBNZCJfnymu2QcoS1NMqBu7Lc8UhN0bNM=\" rel=\"nofollow\" target=\"_blank\">kimberly.ha@kkhadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGFjMmU2ZGYtMmUyMS00ZTdlLWFmYTItNTcyNTY0NTAxMDk5LTExMzQ1Nzc=\/tiny\/IN8bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) &#8212; February 14, 2025\u00a0\u2013 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation &amp; Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100\u2019s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML) patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology. The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival (PFS) rate across all leukemia patients stands at 90.9%, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-813429","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) &#8212; February 14, 2025\u00a0\u2013 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation &amp; Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100\u2019s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML) patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology. The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival (PFS) rate across all leukemia patients stands at 90.9%, &hellip; Continue reading &quot;IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-14T14:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML\",\"datePublished\":\"2025-02-14T14:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/\"},\"wordCount\":1260,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/\",\"name\":\"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=\",\"datePublished\":\"2025-02-14T14:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/","og_locale":"en_US","og_type":"article","og_title":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - Market Newsdesk","og_description":"NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) &#8212; February 14, 2025\u00a0\u2013 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation &amp; Cellular Therapy (TCT) Meetings in Hawaii. The data, previously announced, reinforce INB-100\u2019s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia (AML) patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology. The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival (PFS) rate across all leukemia patients stands at 90.9%, &hellip; Continue reading \"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-14T14:03:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML","datePublished":"2025-02-14T14:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/"},"wordCount":1260,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/","name":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=","datePublished":"2025-02-14T14:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1ODU1NiM2NzUwMTgyIzIxMjMwMDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-presents-positive-phase-1-data-at-tct-2025-highlighting-durability-of-remissions-in-high-risk-aml\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/813429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=813429"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/813429\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=813429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=813429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=813429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}